# A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment

> **NCT06192563** · — · UNKNOWN · sponsor: **Sanofi** · enrollment: 150 (estimated)

## Conditions studied

- Dermatitis Atopic

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT06192563
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-30
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06192563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06192563, "A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06192563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*